Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 6/2016

Open Access 01-06-2016 | Neuroimaging (DJ Brooks, Section Editor)

Advances of Molecular Imaging in Epilepsy

Authors: Marian Galovic, Matthias Koepp

Published in: Current Neurology and Neuroscience Reports | Issue 6/2016

Login to get access

Abstract

Positron emission tomography (PET) is a neuroimaging method that offers insights into the molecular functioning of a human brain. It has been widely used to study metabolic and neurotransmitter abnormalities in people with epilepsy. This article reviews the development of several PET radioligands and their application in studying the molecular mechanisms of epilepsy. Over the last decade, tracers binding to serotonin and γ-aminobutyric acid (GABA) receptors have been used to delineate the location of the epileptic focus. PET studies have examined the role of opioids, cannabinoids, acetylcholine, and dopamine in modulating neuronal hyperexcitability and seizure termination. In vivo analyses of drug transporters, e.g., P-glycoprotein, have increased our understanding of pharmacoresistance that could inform new therapeutic strategies. Finally, PET experiments targeting neuroinflammation and glutamate receptors might guide the development of novel biomarkers of epileptogenesis.
Literature
1.
Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979;6:371–88.CrossRefPubMed
2.
Kuhl DE, Engel J, Phelps ME, Selin C. Epileptic patterns of local cerebral metabolism and perfusion in humans determined by emission computed tomography of 18FDG and 13NH3. Ann Neurol. 1980;8:348–60.CrossRefPubMed
3.
la Fougère C, Rominger A, Förster S, Geisler J, Bartenstein P. PET and SPECT in epilepsy: a critical review. Epilepsy Behav. 2009;15:50–5.CrossRefPubMed
4.
Laufs H, Richardson MP, Salek-Haddadi A, Vollmar C, Duncan JS, Gale K, et al. Converging PET and fMRI evidence for a common area involved in human focal epilepsies. Neurology. 2011;77:904–10.CrossRefPubMedPubMedCentral
5.
Centeno M, Vollmar C, Stretton J, Symms MR, Thompson PJ, Richardson MP, et al. Structural changes in the temporal lobe and piriform cortex in frontal lobe epilepsy. Epilepsy Res. 2014;108:978–81.CrossRefPubMedPubMedCentral
6.
Piredda S, Gale K. A crucial epileptogenic site in the deep prepiriform cortex. Nature. 1985;317:623–5.CrossRefPubMed
7.
Vivash L, Gregoire M-C, Lau EW, Ware RE, Binns D, Roselt P, et al. 18F-flumazenil: a γ-aminobutyric acid A-specific PET radiotracer for the localization of drug-resistant temporal lobe epilepsy. J Nucl Med. 2013;54:1270–7.CrossRefPubMed
8.
During MJ, Spencer DD. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet. 1993;341:1607–10.CrossRefPubMed
9.
Yeh GC, Bonhaus DW, Nadler JV, McNamara JO. N-methyl-D-aspartate receptor plasticity in kindling: quantitative and qualitative alterations in the N-methyl-D-aspartate receptor-channel complex. Proc Natl Acad Sci U S A. 1989;86:8157–60.CrossRefPubMedPubMedCentral
10.
Stasheff SF, Anderson WW, Clark S, Wilson WA. NMDA antagonists differentiate epileptogenesis from seizure expression in an in vitro model. Science. 1989;245:648–51.CrossRefPubMed
11.
Kumlien E, Hartvig P, Valind S, Oye I, Tedroff J, Långström B. NMDA-receptor activity visualized with (S)-[N-methyl-11C]ketamine and positron emission tomography in patients with medial temporal lobe epilepsy. Epilepsia. 1999;40:30–7.CrossRefPubMed
12.
McGinnity CJ, Hammers A, Riaño Barros DA, Luthra SK, Jones PA, Trigg W, et al. Initial evaluation of 18F-GE-179, a putative PET Tracer for activated N-methyl D-aspartate receptors. J Nucl Med. 2014;55:423–30.CrossRefPubMed
13.••
McGinnity CJ, Koepp MJ, Hammers A, Riaño Barros DA, Pressler RM, Luthra S, et al. NMDA receptor binding in focal epilepsies. J Neurol Neurosurg Psychiatr. 2015;86:1150–7. This is the first study to demonstrate a global increase of NMDA receptor activation in epilepsy patients. Interestingly, those on antidepressants had a markedly lower NMDA receptor binding.CrossRefPubMedPubMedCentral
14.
Feldmann M, Koepp M. P-glycoprotein imaging in temporal lobe epilepsy: in vivo PET experiments with the Pgp substrate [11C]-verapamil. Epilepsia. 2012;53 Suppl 6:60–3.CrossRefPubMed
15.
Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med. 2003;348:1442–8.CrossRefPubMed
16.
Volk HA, Burkhardt K, Potschka H, Chen J, Becker A, Loscher W. Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience. 2004;123:751–9.CrossRefPubMed
17.
Sisodiya SM, Lin W-R, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain. 2002;125:22–31.CrossRefPubMed
18.
Eyal S, Ke B, Muzi M, Link JM, Mankoff DA, Collier AC, et al. Regional P-glycoprotein activity and inhibition at the human blood–brain barrier as imaged by positron emission tomography. Clin Pharmacol Ther. 2010;87:579–85.CrossRefPubMedPubMedCentral
19.
Wagner CC, Bauer M, Karch R, Feurstein T, Kopp S, Chiba P, et al. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood–brain barrier with (R)-11C-verapamil and PET. J Nucl Med. 2009;50:1954–61.CrossRefPubMedPubMedCentral
20.
Langer O, Bauer M, Hammers A, Karch R, Pataraia E, Koepp MJ, et al. Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia. 2007;48:1774–84.CrossRefPubMed
21.••
Feldmann M, Asselin M-C, Liu J, Wang S, McMahon A, Anton-Rodriguez J, et al. P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case–control study. Lancet Neurol. 2013;12:777–85. Feldman et al. demonstrated increased activity of the drug transporter P-glycoprotein in pharmacoresistant epilepsy patients. This could contribute to multidrug resistance by reducing the intracellular concentration of antiepileptic drugs.CrossRefPubMed
22.
Shin JW, Chu K, Shin SA, Jung KH, Lee ST, Lee YS, et al. Clinical applications of simultaneous PET/MR imaging using (R)-[11C]-verapamil with cyclosporine A: preliminary results on a surrogate marker of drug-resistant epilepsy. AJNR Am J Neuroradiol. 2015.
23.
Bauer M, Karch R, Zeitlinger M, Liu J, Koepp MJ, Asselin M-C, et al. In vivo P-glycoprotein function before and after epilepsy surgery. Neurology. 2014;83:1326–31.CrossRefPubMedPubMedCentral
24.
25.
Seneca N, Zoghbi SS, Liow J-S, Kreisl W, Herscovitch P, Jenko K, et al. Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein. J Nucl Med. 2009;50:807–13.
26.
Amhaoul H, Hamaide J, Bertoglio D, Reichel SN, Verhaeghe J, Geerts E, et al. Brain inflammation in a chronic epilepsy model: evolving pattern of the translocator protein during epileptogenesis. Neurobiol Dis. 2015;82:526–39.CrossRefPubMed
27.
Das A, Wallace GC, Holmes C, McDowell ML, Smith JA, Marshall JD, et al. Hippocampal tissue of patients with refractory temporal lobe epilepsy is associated with astrocyte activation, inflammation, and altered expression of channels and receptors. Neuroscience. 2012;220:237–46.CrossRefPubMedPubMedCentral
28.
Dedeurwaerdere S, Callaghan PD, Pham T, Rahardjo GL, Amhaoul H, Berghofer P, et al. PET imaging of brain inflammation during early epileptogenesis in a rat model of temporal lobe epilepsy. EJNMMI Res. 2012;2:60.CrossRefPubMedPubMedCentral
29.
Kim J-E, Choi H-C, Song H-K, Jo S-M, Kim D-S, Choi S-Y, et al. Levetiracetam inhibits interleukin-1 beta inflammatory responses in the hippocampus and piriform cortex of epileptic rats. Neurosci Lett. 2010;471:94–9.CrossRefPubMed
30.
Amhaoul H, Staelens S, Dedeurwaerdere S. Imaging brain inflammation in epilepsy. Neuroscience. 2014;279:238–52.CrossRefPubMed
31.
Ory D, Planas A, Dresselaers T, Gsell W, Postnov A, Celen S, et al. PET imaging of TSPO in a rat model of local neuroinflammation induced by intracerebral injection of lipopolysaccharide. Nucl Med Biol. 2015;42:753–61.CrossRefPubMed
32.
Sandiego CM, Gallezot J-D, Pittman B, Nabulsi N, Lim K, Lin S-F, et al. Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. Proc Natl Acad Sci U S A. 2015;112:12468–73.CrossRefPubMedPubMedCentral
33.
Banati RB, Goerres GW, Myers R, Gunn RN, Turkheimer FE, Kreutzberg GW, et al. [11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen's encephalitis. Neurology. 1999;53:2199–203.CrossRefPubMed
34.
Kumar A, Chugani HT, Luat A, Asano E, Sood S. Epilepsy surgery in a case of encephalitis: use of 11C-PK11195 positron emission tomography. Pediatr Neurol. 2008;38:439–42.CrossRefPubMed
35.
Goerres GW, Revesz T, Duncan J, Banati RB. Imaging cerebral vasculitis in refractory epilepsy using [(11)C](R)-PK11195 positron emission tomography. AJR Am J Roentgenol. 2001;176:1016–8.CrossRefPubMed
36.••
Gershen LD, Zanotti-Fregonara P, Dustin IH, Liow JS, Hirvonen J, Kreisl WC, et al. Neuroinflammation in temporal lobe epilepsy measured using positron emission tomographic imaging of translocator protein. JAMA Neurol. 2015;72:882–8. Gershen et al. showed increased TSPO activity in the temporal lobes of epilepsy patients. This supports the role of neuroinflammation in epilepsy and epileptogenesis.CrossRefPubMed
37.
Hirvonen J, Kreisl WC, Fujita M, Dustin I, Khan O, Appel S, et al. Increased in vivo expression of an inflammatory marker in temporal lobe epilepsy. J Nucl Med. 2012;53:234–40.CrossRefPubMed
38.
39.
Louw D, Sutherland GR, Glavin GB, Girvin J. A study of monoamine metabolism in human epilepsy. Can J Neurol Sci. 1989;16:394–7.PubMed
40.
Chugani DC. α-methyl-L-tryptophan: mechanisms for tracer localization of epileptogenic brain regions. Biomarkers Med. 2011;5:567–75.CrossRef
41.
Chugani DC, Chugani HT, Muzik O, Shah JR, Shah AK, Canady A, et al. Imaging epileptogenic tubers in children with tuberous sclerosis complex using alpha-[11C]methyl-L-tryptophan positron emission tomography. Ann Neurol. 1998;44:858–66.CrossRefPubMed
42.
Asano E, Chugani DC, Muzik O, Shen C, Juhász C, Janisse J, et al. Multimodality imaging for improved detection of epileptogenic foci in tuberous sclerosis complex. Neurology. 2000;54:1976–84.CrossRefPubMed
43.
Kagawa K, Chugani DC, Asano E, Juhász C, Muzik O, Shah A, et al. Epilepsy surgery outcome in children with tuberous sclerosis complex evaluated with alpha-[11C]methyl-L-tryptophan positron emission tomography (PET). J Child Neurol. 2005;20:429–38.CrossRefPubMed
44.••
Chugani HT, Luat AF, Kumar A, Govindan R, Pawlik K, Asano E. α-[11C]-methyl-L-tryptophan—PET in 191 patients with tuberous sclerosis complex. Neurology. 2013;81:674–80. Chugani et al. reported findings of [11C]AMT-PET in a large cohort of patients with tuberous sclerosis complex. There was excellent agreement between lateralization on ictal EEG and PET, whereas PET provided additional localizing information in certain cases.CrossRefPubMedPubMedCentral
45.•
Rubí S, Costes N, Heckemann RA, Bouvard S, Hammers A, Martí Fuster B, et al. Positron emission tomography with α-[11C]methyl-L-tryptophan in tuberous sclerosis complex-related epilepsy. Epilepsia. 2013;54:2143–50. Rubí et al. demonstrated the use of [11C]AMT-PET in one of few studies performed outside of Detroit. The found low sensitivity but excellent specificity for focus localization in a small external validation cohort of tuberous sclerosis patients.CrossRefPubMed
46.
Juhász C, Chugani DC, Padhye UN, Muzik O, Shah A, Asano E, et al. Evaluation with alpha-[11C]methyl-L-tryptophan positron emission tomography for reoperation after failed epilepsy surgery. Epilepsia. 2004;45:124–30.CrossRefPubMed
47.
Juhász C, Chugani DC, Muzik O, Shah A, Asano E, Mangner TJ, et al. Alpha-methyl-L-tryptophan PET detects epileptogenic cortex in children with intractable epilepsy. Neurology. 2003;60:960–8.CrossRefPubMed
48.
Garibotto V, Picard F. Nuclear medicine imaging in epilepsy. Epileptologie. 2013;30:109–21.
49.•
Martinez A, Finegersh A, Cannon DM, Dustin I, Nugent A, Herscovitch P, et al. The 5-HT1A receptor and 5-HT transporter in temporal lobe epilepsy. Neurology. 2013;80:1465–71. Martinez et al. found a reduced activity of the serotonin transporter in epilepsy patients with comorbid depression. This might represent an attempt of the brain to compensate for reduced serotonin levels in concomitant depression.CrossRefPubMedPubMedCentral
50.
Toczek MT, Carson RE, Lang L, Ma Y, Spanaki MV, Der MG, et al. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology. 2003;60:749–56.CrossRefPubMed
51.
Savic I, Lindstrom P, Gulyás B, Halldin C, Andrée B, Farde L. Limbic reductions of 5-HT1A receptor binding in human temporal lobe epilepsy. Neurology. 2004;62:1343–51.CrossRefPubMed
52.
Giovacchini G, Toczek MT, Bonwetsch R, Bagic A, Lang L, Fraser C, et al. 5-HT 1A receptors are reduced in temporal lobe epilepsy after partial-volume correction. J Nucl Med. 2005;46:1128–35.PubMedPubMedCentral
53.
Hasler G, Bonwetsch R, Giovacchini G, Toczek MT, Bagic A, Luckenbaugh DA, et al. 5-HT1A receptor binding in temporal lobe epilepsy patients with and without major depression. BPS. 2007;62:1258–64.
54.
Liew CJ, Lim Y-M, Bonwetsch R, Shamim S, Sato S, Reeves-Tyer P, et al. 18F-FCWAY and 18F-FDG PET in MRI-negative temporal lobe epilepsy. Epilepsia. 2009;50:234–9.CrossRefPubMedPubMedCentral
55.
Merlet I, Ostrowsky K, Costes N, Ryvlin P, Isnard J, Faillenot I, et al. 5-HT1A receptor binding and intracerebral activity in temporal lobe epilepsy: an [18F]MPPF-PET study. Brain. 2004;127:900–13.CrossRefPubMed
56.
Merlet I, Ryvlin P, Costes N, Dufournel D, Isnard J, Faillenot I, et al. Statistical parametric mapping of 5-HT1A receptor binding in temporal lobe epilepsy with hippocampal ictal onset on intracranial EEG. Neuroimage. 2004;22:886–96.CrossRefPubMed
57.
Didelot A, Ryvlin P, Lothe A, Merlet I, Hammers A, Mauguière F. PET imaging of brain 5-HT1A receptors in the preoperative evaluation of temporal lobe epilepsy. Brain. 2008;131:2751–64.CrossRefPubMed
58.
Didelot A, Mauguière F, Redouté J, Bouvard S, Lothe A, Reilhac A, et al. Voxel-based analysis of asymmetry index maps increases the specificity of 18F-MPPF PET abnormalities for localizing the epileptogenic zone in temporal lobe epilepsies. J Nucl Med. 2010;51:1732–9.CrossRefPubMed
59.
Theodore WH, Hasler G, Giovacchini G, Kelley K, Reeves-Tyer P, Herscovitch P, et al. Reduced hippocampal 5HT1A PET receptor binding and depression in temporal lobe epilepsy. Epilepsia. 2007;48:1526–30.CrossRefPubMed
60.
Lothe A, Didelot A, Hammers A, Costes N, Saoud M, Gilliam F, et al. Comorbidity between temporal lobe epilepsy and depression: a [18F]MPPF PET study. Brain. 2008;131:2765–82.CrossRefPubMed
61.
Cannon DM, Ichise M, Rollis D, Klaver JM, Gandhi SK, Charney DS, et al. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. BPS. 2007;62:870–7.
62.
Haut SR, Albin RL. Dopamine and epilepsy: hints of complex subcortical roles. Neurology. 2008;71:784–5.CrossRefPubMed
63.
64.
Deransart C, Riban V, Lê B, Marescaux C, Depaulis A. Dopamine in the striatum modulates seizures in a genetic model of absence epilepsy in the rat. Neuroscience. 2000;100:335–44.CrossRefPubMed
65.
Biraben A, Semah F, Ribeiro M-J, Douaud G, Remy P, Depaulis A. PET evidence for a role of the basal ganglia in patients with ring chromosome 20 epilepsy. Neurology. 2004;63:73–7.CrossRefPubMed
66.
Bouilleret V, Semah F, Biraben A, Taussig D, Chassoux F, Syrota A, et al. Involvement of the basal ganglia in refractory epilepsy: an 18F-fluoro-L-DOPA PET study using 2 methods of analysis. J Nucl Med. 2005;46:540–7.PubMed
67.
Bouilleret V, Semah F, Chassoux F, Mantzaridez M, Biraben A, Trebossen R, et al. Basal ganglia involvement in temporal lobe epilepsy: a functional and morphologic study. Neurology. 2008;70:177–84.CrossRefPubMed
68.
Werhahn KJ, Landvogt C, Klimpe S, Buchholz H-G, Yakushev I, Siessmeier T, et al. Decreased dopamine D2/D3-receptor binding in temporal lobe epilepsy: an [18F]fallypride PET study. Epilepsia. 2006;47:1392–6.CrossRefPubMed
69.
Yakushev IY, Dupont E, Buchholz H-G, Tillmanns J, Debus F, Cumming P, et al. In vivo imaging of dopamine receptors in a model of temporal lobe epilepsy. Epilepsia. 2010;51:415–22.CrossRefPubMed
70.
Landvogt C, Buchholz H-G, Bernedo V, Schreckenberger M, Werhahn KJ. Alteration of dopamine D2/D3 receptor binding in patients with juvenile myoclonic epilepsy. Epilepsia. 2010;51:1699–706.CrossRefPubMed
71.
Bernedo Paredes VE, Buchholz H-G, Gartenschläger M, Breimhorst M, Schreckenberger M, Werhahn KJ. Reduced D2/D3 receptor binding of extrastriatal and striatal regions in temporal lobe epilepsy. PLoS ONE. 2015;10, e0141098.CrossRefPubMedPubMedCentral
72.
Fedi M, Berkovic SF, Scheffer IE, O'Keefe G, Marini C, Mulligan R, et al. Reduced striatal D1 receptor binding in autosomal dominant nocturnal frontal lobe epilepsy. Neurology. 2008;71:795–8.CrossRefPubMed
73.
Ciumas C, Wahlin T-BR, Jucaite A, Lindstrom P, Halldin C, Savic I. Reduced dopamine transporter binding in patients with juvenile myoclonic epilepsy. Neurology. 2008;71:788–94.CrossRefPubMed
74.
Ciumas C, Wahlin T-BR, Espino C, Savic I. The dopamine system in idiopathic generalized epilepsies: identification of syndrome-related changes. Neuroimage. 2010;51:606–15.CrossRefPubMed
75.
Odano I, Varrone A, Savic I, Ciumas C, Karlsson P, Jucaite A, et al. Quantitative PET analyses of regional [11C]PE2I binding to the dopamine transporter—application to juvenile myoclonic epilepsy. Neuroimage. 2012;59:3582–93.CrossRefPubMed
76.
Rocha L, Alonso-Vanegas M, Villeda-Hernández J, Mújica M, Cisneros-Franco JM, López-Gómez M, et al. Dopamine abnormalities in the neocortex of patients with temporal lobe epilepsy. Neurobiol Dis. 2012;45:499–507.CrossRefPubMed
77.
Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 2003;302:84–8.CrossRefPubMed
78.
Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther. 2003;307:129–37.CrossRefPubMed
79.
Falenski KW, Blair RE, Sim-Selley LJ, Martin BR, DeLorenzo RJ. Status epilepticus causes a long-lasting redistribution of hippocampal cannabinoid type 1 receptor expression and function in the rat pilocarpine model of acquired epilepsy. Neuroscience. 2007;146:1232–44.CrossRefPubMedPubMedCentral
80.
Karlócai MR, Tóth K, Watanabe M, Ledent C, Juhász G, Freund TF, et al. Redistribution of CB1 cannabinoid receptors in the acute and chronic phases of pilocarpine-induced epilepsy. PLoS ONE. 2011;6, e27196.CrossRefPubMedPubMedCentral
81.
Chen K, Neu A, Howard AL, Földy C, Echegoyen J, Hilgenberg L, et al. Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcitability caused by developmental seizures. J Neurosci. 2007;27:46–58.CrossRefPubMed
82.
Goffin K, Van Paesschen W, Van Laere K. In vivo activation of endocannabinoid system in temporal lobe epilepsy with hippocampal sclerosis. Brain. 2011;134:1033–40.CrossRefPubMed
83.
Riaño Barros DA, McGinnity CJ, Rosso L, Heckemann RA, Howes OD, Brooks DJ, et al. Test-retest reproducibility of cannabinoid-receptor type 1 availability quantified with the PET ligand [11C]MePPEP. Neuroimage. 2014;97:151–62.CrossRefPubMedPubMedCentral
84.
Koepp MJ, Richardson MP, Brooks DJ, Duncan JS. Focal cortical release of endogenous opioids during reading-induced seizures. Lancet. 1998;352:952–5.CrossRefPubMed
85.
Bartenstein PA, Duncan JS, Prevett MC, Cunningham VJ, Fish DR, Jones AK, et al. Investigation of the opioid system in absence seizures with positron emission tomography. J Neurol Neurosurg Psychiatr. 1993;56:1295–302.CrossRefPubMedPubMedCentral
86.
Hammers A, Asselin M-C, Hinz R, Kitchen I, Brooks DJ, Duncan JS, et al. Upregulation of opioid receptor binding following spontaneous epileptic seizures. Brain. 2007;130:1009–16.CrossRefPubMed
87.
McGinnity CJ, Shidahara M, Feldmann M, Keihaninejad S, Riaño Barros DA, Gousias IS, et al. Quantification of opioid receptor availability following spontaneous epileptic seizures: correction of [11C]diprenorphine PET data for the partial-volume effect. Neuroimage. 2013;79:72–80.CrossRefPubMed
88.
De Fusco M, Becchetti A, Patrignani A, Annesi G, Gambardella A, Quattrone A, et al. The nicotinic receptor beta 2 subunit is mutant in nocturnal frontal lobe epilepsy. Nat Genet. 2000;26:275–6.CrossRefPubMed
89.
Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, Sutherland GR, et al. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet. 1995;11:201–3.CrossRefPubMed
90.
Picard F, Bruel D, Servent D, Saba W, Fruchart-Gaillard C, Schöllhorn-Peyronneau M-A, et al. Alteration of the in vivo nicotinic receptor density in ADNFLE patients: a PET study. Brain. 2006;129:2047–60.CrossRefPubMed
91.
Löscher W, Hirsch LJ, Schmidt D. The enigma of the latent period in the development of symptomatic acquired epilepsy—traditional view versus new concepts. Epilepsy Behav. 2015;52:78–92.CrossRefPubMed
Metadata
Title
Advances of Molecular Imaging in Epilepsy
Authors
Marian Galovic
Matthias Koepp
Publication date
01-06-2016
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 6/2016
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-016-0660-7

Other articles of this Issue 6/2016

Current Neurology and Neuroscience Reports 6/2016 Go to the issue

Neuroimaging (DJ Brooks, Section Editor)

Imaging Systemic Dysfunction in Parkinson’s Disease

Critical Care (SA Mayer, Section Editor)

Brain Multimodality Monitoring: Updated Perspectives

Genetics (V Bonifati, Section Editor)

ALS: Recent Developments from Genetics Studies

Sleep (M Thorpy and M Billiard Section Editors)

The Risk of Sleep Disorder Among Persons with Mild Traumatic Brain Injury

Behavior (H Kirshner, Section Editor)

Kleine-Levin Syndrome

Neurology of Systemic Diseases (J Biller, Section Editor)

Neurologic Complications in the Intensive Care Unit